MiRNA-based therapy for Myocardial infarction: Sox2 protects against ischemia/reperfusion injury and promotes cardiomyocyte survival via up regulation of pro-survivval protein Bcl-2, 2/April/2015, 13.40

Molecular therapy for DM: Ars2 (arsenite-resistance protein 2/Serrate RNA effector molecule homolog) inhibits gluconeogenesis and hyperglycemia via up regulation of Cyclin D1, 2/April/2015, 12.01 pm
April 2, 2015
MiRNA-based Regenerative therapy for DM: MiRNA-25 promotes an insulin sensitized state via up regulation of reprogramming protein Lin28, 2/April/2015, 17.30
April 2, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, MiRNA-based therapy for Myocardial infarction: Sox2 protects against ischemia/reperfusion injury and promotes cardiomyocyte survival via up regulation of pro-survivval protein Bcl-2, 2/April/2015, 13.40, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: Sox2, by increasing the expression of its target gene, it may increase the expression of pro-survival protein Bcl-2. Thereby, it may inhibit myocardial apoptosis. Thus, pharmacological formulations encompassing “Sox2 activators” may be used to treat myocardial infarction. 

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How Sox2 increases the expression of Bcl-2

Comments are closed.